Je was op zoek naar: attenuated (Duits - Deens)

fluvacc – live attenuated replication-defective influenza vaccine
fluvacc - live attenuated replication-defective influenza vaccine

titel des dokuments note for guidance on the use of bovine serum in the manufacture of human biological medicinal products points to consider on quality aspects of medicinal products containing active substances produced by stable transgene expression in higher plants revision of note for guidance on minimising the risks of tse transmission via medicinal products points to consider on the development of live attenuated influenza vaccines
titel på dokumentet note for guidance on the use of bovine serum in the manufacture of human biological medicinal products points to consider on quality aspects of medicinal products containing active substances produced by stable transgene expression in higher plants revision of note for guidance on minimising the risks of tse transmission via medicinal products points to consider on the development of live attenuated influenza vaccines

note for guidance on pharmacokinetic studies in man points to consider on live attenuated influenza vaccines guidance on requirements for pharmaceutical/clinical documentation for cell culture influenza vaccines points to consider on xenogeneic cell therapy note for guidance on comparability of medicinal products containing biotechnology-derived proteins as active substance note for guidance on the use of medicinal products during pregnancy: need for post-marketing data note for guidance on risk assessment of medicinal products on human reproductive and development toxicities: from data to labelling revision of the note for guidance on harmonisation of requirements for influenza vaccines
note for guidance on pharmacokinetic studies in man points to consider on live attenuated influenza vaccines guidance on requirements for pharmaceutical/ clinical documentation for cell culture influenza vaccines points to consider on xenogeneic cell therapy note for guidance on comparability of medicinal products containing biotechnology- derived proteins as active substance note for guidance on the use of medicinal products during pregnancy: need for post- marketing data note for guidance on risk assessment of medicinal products on human reproductive and development toxicities: from data to labelling revision of the note for guidance on harmonisation of requirements for influenza vaccines